Platinum based theranostics nanoplatforms for antitumor applications

Platinum (Pt) based nanoplatforms are biocompatible nanoagents with photothermal antitumor performance, while exhibiting excellent radiotherapy sensitization properties. Pt-nanoplatforms have extensive research prospects in the realm of cancer treatment due to their highly selective and minimally invasive treatment mode with low damage, and integrated diagnosis and treatment with image monitoring and collaborative drug delivery. Platinum based anticancer chemotherapeutic drugs can kill tumor cells by damaging DNA through chemotherapy. Meanwhile, Pt-nanoplatforms also have good electrocatalytic activity, which can mediate novel electrodynamic therapy. Simultaneously, Pt(II) based compounds also have potential as photosensitizers in photodynamic therapy for malignant tumors. Pt-nanoplatforms can also modulate the immunosuppressive environment and synergistically ablate tumor cells in combination with immune checkpoint inhibitors. This article reviews the research progress of platinum based nanoplatforms in new technologies for cancer therapy, starting from widely representative examples of platinum based nanoplatforms in chemotherapy, electrodynamic therapy, photodynamic therapy, photothermal therapy, and immunotherapy. Finally, multimodal imaging techniques of platinum based nanoplatforms for biomedical diagnosis are briefly discussed.

Medienart:

E-Artikel

Erscheinungsjahr:

2023

Erschienen:

2023

Enthalten in:

Zur Gesamtaufnahme - volume:11

Enthalten in:

Journal of materials chemistry. B - 11(2023), 35 vom: 13. Sept., Seite 8387-8403

Sprache:

Englisch

Beteiligte Personen:

Li, Heying [VerfasserIn]
Cheng, Shaowen [VerfasserIn]
Zhai, Jingming [VerfasserIn]
Lei, Kun [VerfasserIn]
Zhou, Ping [VerfasserIn]
Cai, Kaiyong [VerfasserIn]
Li, Jinghua [VerfasserIn]

Links:

Volltext

Themen:

49DFR088MY
Antineoplastic Agents
Journal Article
Platinum
Research Support, Non-U.S. Gov't
Review

Anmerkungen:

Date Completed 14.09.2023

Date Revised 14.09.2023

published: Electronic

Citation Status MEDLINE

doi:

10.1039/d3tb01035j

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM360805787